Skip to main content

LUP Student Papers

LUND UNIVERSITY LIBRARIES

Transparency in the Black Box

Schnitzer, Sofie LU and Tiruwuha, Mathewos Hawariat LU (2024) SYSK16 20241
Department of Informatics
Abstract
The integration of Artificial Intelligence (AI) into drug development introduces significant opportunities and ethical challenges, particularly with the use of complex "Black Box" AI systems. This study investigates how the drug development industry addresses ethical concerns associated with AI, focusing on compliance with European Union (EU) regulations, including the Assessment List for Trustworthy Artificial Intelligence (ALTAI) and the Artificial Intelligence Act (AI Act). Through a literature review and qualitative interviews with industry professionals, this research explores how the industry manages the trade-off between harnessing AI's capabilities and meeting ethical standards for transparency. The findings highlight a strong... (More)
The integration of Artificial Intelligence (AI) into drug development introduces significant opportunities and ethical challenges, particularly with the use of complex "Black Box" AI systems. This study investigates how the drug development industry addresses ethical concerns associated with AI, focusing on compliance with European Union (EU) regulations, including the Assessment List for Trustworthy Artificial Intelligence (ALTAI) and the Artificial Intelligence Act (AI Act). Through a literature review and qualitative interviews with industry professionals, this research explores how the industry manages the trade-off between harnessing AI's capabilities and meeting ethical standards for transparency. The findings highlight a strong industry emphasis on the importance of explainability in AI systems, which is crucial for building trust and adhering to regulatory frameworks. The thesis also examines the broader implications of these ethical issues for the future use of AI in drug development, proposing a framework that promotes both innovation and ethical compliance. The gathered perspectives largely reflect a proactive approach by the industry to meet EU standards, underscoring a commitment to ethical AI deployment. This research enhances the understanding of the relationship between technological progress and ethical guidelines in drug development, emphasizing the importance of transparency and explainability in meeting industry and regulatory expectations. (Less)
Popular Abstract (Swedish)
Integrationen av Artificiell Intelligens (AI) i läkemedelsutvecklingen medför betydande möjligheter och etiska utmaningar, särskilt med användning av komplexa "Black Box" AI-system. Denna studie undersöker hur läkemedelsindustrin hanterar etiska frågor kopplade till AI, med fokus på efterlevnad av EU:s regelverk, inklusive Assessment List for Trustworthy Artificial Intelligence (ALTAI) samt Artificial Intelligence Act (AI Act). Genom en litteraturöversikt och kvalitativa intervjuer med branschfolk utforskas hur industrin balanserar mellan att utnyttja AI:s kapacitet och att uppfylla etiska standarder för transparens. Resultaten betonar en stark industriell betoning på vikten av förklarbarhet i AI-system, vilket är avgörande för att bygga... (More)
Integrationen av Artificiell Intelligens (AI) i läkemedelsutvecklingen medför betydande möjligheter och etiska utmaningar, särskilt med användning av komplexa "Black Box" AI-system. Denna studie undersöker hur läkemedelsindustrin hanterar etiska frågor kopplade till AI, med fokus på efterlevnad av EU:s regelverk, inklusive Assessment List for Trustworthy Artificial Intelligence (ALTAI) samt Artificial Intelligence Act (AI Act). Genom en litteraturöversikt och kvalitativa intervjuer med branschfolk utforskas hur industrin balanserar mellan att utnyttja AI:s kapacitet och att uppfylla etiska standarder för transparens. Resultaten betonar en stark industriell betoning på vikten av förklarbarhet i AI-system, vilket är avgörande för att bygga förtroende och följa regelverk. Uppsatsen undersöker också de bredare konsekvenserna av dessa etiska frågor för framtida användning av AI i läkemedelsutveckling, och föreslår ett ramverk som främjar både innovation och etisk efterlevnad. Insamlade perspektiv reflekterar i stor utsträckning en proaktiv inställning från industrin för att möta EU-standarder, vilket understryker ett åtagande för etiskt AI-implementering. Forskningen förbättrar förståelsen för sambandet mellan tekniska framsteg och etiska riktlinjer och perspektiv i läkemedelsutvecklingen, och betonar vikten av transparens och förklarbarhet. (Less)
Please use this url to cite or link to this publication:
author
Schnitzer, Sofie LU and Tiruwuha, Mathewos Hawariat LU
supervisor
organization
alternative title
The drug development industry’s perspective on ethical concerns posed by Black Box AI, and how well it aligns with EU requirements
course
SYSK16 20241
year
type
M2 - Bachelor Degree
subject
keywords
Artificial Intelligence, Drug Development, Ethics, Explainability, EU Requirements
language
English
id
9162275
date added to LUP
2024-06-12 14:45:13
date last changed
2024-06-12 14:45:13
@misc{9162275,
  abstract     = {{The integration of Artificial Intelligence (AI) into drug development introduces significant opportunities and ethical challenges, particularly with the use of complex "Black Box" AI systems. This study investigates how the drug development industry addresses ethical concerns associated with AI, focusing on compliance with European Union (EU) regulations, including the Assessment List for Trustworthy Artificial Intelligence (ALTAI) and the Artificial Intelligence Act (AI Act). Through a literature review and qualitative interviews with industry professionals, this research explores how the industry manages the trade-off between harnessing AI's capabilities and meeting ethical standards for transparency. The findings highlight a strong industry emphasis on the importance of explainability in AI systems, which is crucial for building trust and adhering to regulatory frameworks. The thesis also examines the broader implications of these ethical issues for the future use of AI in drug development, proposing a framework that promotes both innovation and ethical compliance. The gathered perspectives largely reflect a proactive approach by the industry to meet EU standards, underscoring a commitment to ethical AI deployment. This research enhances the understanding of the relationship between technological progress and ethical guidelines in drug development, emphasizing the importance of transparency and explainability in meeting industry and regulatory expectations.}},
  author       = {{Schnitzer, Sofie and Tiruwuha, Mathewos Hawariat}},
  language     = {{eng}},
  note         = {{Student Paper}},
  title        = {{Transparency in the Black Box}},
  year         = {{2024}},
}